Filed by Bristol-Myers Squibb Company

Pursuant to Rule 425 of the Securities Act of 1933

and deemed filed pursuant to Rule 14a-12

of the Securities Exchange Act of 1934

Form S-4 File No.: 333-229464 Subject Company: Celgene Corporation

SEC File No.: 001-34912

Explanatory Note: The following is a set of materials regarding Bristol-Myers Squibb Company provided to Celgene Corporation employees on February 19, 2019.

Focus on BMS Marketed Portfolio

At Bristol-Myers Squibb, we work every day to discover, develop and deliver transformational medicines for patients with serious diseases. In 2007, we embarked on a bold strategy to create a new business model combining the innovation and agility of a biotech with the reach and resources of a major pharma company. Twelve years later, this biopharma model has delivered significant growth for the company and value for our patients and shareholders.

Our marketed portfolio includes innovative medicines targeting hard-to-treat diseases. We focus on the specialty therapeutic areas of oncology, immunoscience and cardiovascular diseases. The company's top brands today include Opdivo, Eliquis, Orencia, Sprycel and Yervoy .

Bristol-Myers Squibb Marketed Oncology Portfolio

About Opdivo

Opdivo (nivolumab) is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body's own immune system to help restore anti-tumor immune response. By harnessing the body's own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Opdivo 's leading global development program is based on Bristol-Myers Squibb's scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has enrolled more than 25,000 patients. The Opdivo trials have contributed to gaining a deeper understanding of the potential role of biomarkers in patient care, particularly regarding how patients may benefit from Opdivo across the continuum of PD-L1 expression.

Not for Promotional Purposes

In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 65 countries, including the United States, the European Union, Japan and China. In October 2015, the Company's Opdivo and Yervoy combination regimen was the first immuno-oncology combination to receive regulatory approval for the treatment of metastatic melanoma and is currently approved in more than 50 countries, including the United States and the European Union.

Bristol-Myers Squibb and Ono Pharmaceutical Co. jointly develop and market Opdivo, with Ono responsible for Japan, South Korea and Taiwan and Bristol-Myers Squibb responsible for the rest of the world.

For more information on Opdivo , please visit Opdivo.com

For more information on immuno-oncology, please visithttps://www.immunooncology.com/

About Yervoy

Yervoy (ipilimumab) was the first immuno-oncology agent approved globally in 2011. Yervoy is a monoclonal antibody that works to activate the immune system by targeting CTLA-4 (cytotoxic T-lymphocyte-associated antigen-4), a protein receptor that downregulates the immune system. Yervoy is approved for unresectable or metastatic melanoma in more than 50 countries. There is a broad, ongoing development program in place for Yervoy spanning multiple tumor types.

For more information on Yervoy , please visit Yervoy.com

About Sprycel

Sprycel first received FDA approval in 2006 for the treatment of adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP) who are resistant or intolerant to prior therapy including imatinib. At that time, Sprycel also received FDA approval for adults with Ph+ acute lymphoblastic leukemia (ALL) who are resistant or intolerant to prior therapy. Sprycel is approved and marketed for these indications in more than 60 countries.

Sprycel is also an FDA-approved treatment for adults with newly diagnosed Ph+ CML-CP and is approved for this indication in more than 50 countries.

Both the FDA and the European Commission approved the expansion of Sprycel's indication to include pediatric patients with Ph+ CML-CP in November 2017 and July 2018.

For more information on Sprycel , please visit Sprycel.com

About Empliciti

Empliciti (elotuzumab) is an immunostimulatory antibody that specifically targets Signaling Lymphocyte Activation Molecule Family member 7 (SLAMF7), a cell-surface glycoprotein. SLAMF7 is expressed on myeloma cells independent of cytogenetic abnormalities. SLAMF7 also is expressed on Natural Killer cells, plasma cells and at lower levels on specific immune cell subsets of differentiated cells within the hematopoietic lineage.

Not for Promotional Purposes

Empliciti has a dual mechanism-of-action. It directly activates the immune system through Natural Killer cells via the SLAMF7 pathway. Empliciti also targets SLAMF7 on myeloma cells, tagging these malignant cells for Natural Killer cell-mediated destruction via antibody-dependent cellular toxicity.

Empliciti was initially approved by the FDA in 2015 in combination with Revlimid (lenalidomide) and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.

Bristol-Myers Squibb and AbbVie are co-developing Empliciti , with Bristol-Myers Squibb solely responsible for commercial activities.

For more information on Empliciti , please visit Empliciti.com

Bristol-Myers Squibb Marketed Innovative Medicines Portfolio

About Eliquis

Eliquis (apixaban) is an oral selective Factor Xa inhibitor. By inhibiting Factor Xa, a key blood clotting protein, Eliquis decreases thrombin generation and blood clot formation. Eliquis is approved for multiple indications based on efficacy and safety data from multiple Phase 3 clinical trials. Eliquis is a prescription medicine indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF); for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery; for the treatment of DVT and PE; and to reduce the risk of recurrent DVT and PE, following initial therapy.

Eliquis is the No. 1 prescribed oral anti-coagulant in the U.S. and the No. 1 prescribed novel oral anti-coagulant in the world.

Bristol-Myers Squibb and Pfizer jointly develop and market Eliquis combining Bristol-Myers Squibb's long-standing strengths in cardiovascular drug development and commercialization with Pfizer's global scale and expertise in this field.

For more information on Eliquis , please visit Eliquis.com

About Orencia

Orencia (abatacept) is an immunomodulator that disrupts the continuous cycle of T-cell activation that characterizes rheumatoid arthritis (RA), thereby inhibiting the production of B-cell derived autoantibodies and proimflammatory cytokines. Approved for the treatment for adult RA, juvenile idiopathic arthritis and adult psoriatic arthritis (PsA), Orencia has been in clinical development for more than 13 years. There are three administration options available for Orencia : intravenous infusion (once-a-month procedure at the doctor's office), prefilled syringe (once-weekly injection that can be done at home after training with a doctor) and the ClickJect™ Autoinjector (once-weekly self-injection approved for use only by adults with moderate to severe RA or active PsA).

For more than two decades, Bristol-Myers Squibb has pioneered research into the body' immune system aimed at discovering and developing medicines that harness immunomodulation to treat disease.

For more information on Orencia , please visit Orencia.com .

Not for Promotional Purposes

Eliquis 10 Million Patients and Counting

February 15, 2018

Cardiovascular diseases has long been an important therapeutic area for Bristol-Myers Squibb and our research and development efforts have led to a number of important treatment options for patients over the past decades. Our priority product, Eliquis (apixaban) , is the No. 1 prescribed oral anti-coagulant in the U.S. and the No. 1 prescribed novel oral anti-coagulant in the world.

Beyond outstanding sales performance, Eliquis is making a significant difference for millions of patients across the globe. Approximately 10 million patients have been treated with Eliquis since its launch in 2013. This means that 10 million people received a therapy that significantly reduced their risk of experiencing a stroke, pulmonary embolism or major bleeding compared with the historical standard of care. When we consider the efficacy and safety profile of Eliquis , we are incredibly proud of the work we do and the differentiated impact we are making on the lives of so many people across the globe.

This milestone is not reached without meaningful contributions from colleagues across the Bristol-Myers Squibb enterprise. To start, Eliquis was discovered and developed by BMS scientists. Colleagues in Medical and HEOR (Health Economics and Outcomes Research) have also played critical roles generating clinical trial and real-world data evidence. Additionally, the Global Product Development and Supply team built a robust manufacturing and supply operation to support the rapid growth of Eliquis ; an operation that recently withstood a devastating hurricane in Puerto Rico with no interruption to global supply.

Last year, in recognition of their strong research advancements, a team of Bristol-Myers Squibb scientists received the prestigious 2018 Sir James Black award from the British Pharmacological Society for their contributions in the discovery of Eliquis.

Not for Promotional Purposes

Attachments

  • Original document
  • Permalink

Disclaimer

Bristol-Myers Squibb Company published this content on 19 February 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 19 February 2019 22:43:02 UTC